Dynavax Technologies Profile



Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for Dynavax Technologies Corporatio are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 9, 2019 and ending today December 8, 2019. Click here to learn more.

Dynavax Technologies Profile

Next fiscal quarter end is expected on December 31, 2019. Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor stimulation. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California. Dynavax Technologies operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 249 people. more
Dynavax Technologies Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Dynavax Technologies SEC Filings
Dynavax Technologies SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDynavax Technologies Corporatio
CEO and DirectorEddie GrayView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCalifornia; U.S.A
Business Address2929 Seventh Street
ExchangeBATS Exchange
CIK Number0001029142
Phone510 848 5100
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestNovember 15, 2019
Dynavax Technologies Corporatio (DVAX) is traded on BATS Exchange in USA. It is located in 2929 Seventh Street and employs 249 people. Dynavax Technologies is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 384.09 M. Dynavax Technologies conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 83.68 M outstanding shares of which 14.99 M shares are currently shorted by private and institutional investors with about 14.12 trading days to cover. DYNAVAX TECHNOLOG currently holds about 140.49 M in cash with (98.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16.
Check Dynavax Technologies Probability Of Bankruptcy

Ownership Allocation (%)

Dynavax Technologies Target Price Odds Analysis

Odds Below 5.7HorizonTargetOdds Above 5.7
88.81%30 days 5.70 11.13%
Based on normal probability distribution, the odds of Dynavax Technologies to move above current price in 30 days from now is about 11.13 (This Dynavax Technologies Corporatio probability density function shows the probability of Dynavax Technologies Stock to fall within a particular range of prices over 30 days) .

Dynavax Technologies Top Holders

Dynavax Technologies Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Federated Investors IncCommon Shares8.8 M31.3 M
Bain Capital Life Sciences Investors LlcCommon Shares8.5 M30.3 M
Susquehanna International Group LlpCall Options915.2 K3.3 M
View Dynavax Technologies Diagnostics

Dynavax Technologies Corporatio Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Dynavax Technologies Key Fundamentals

Dynavax Technologies Against Markets

Did you try this?

Run Fundamentals Comparison Now


Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module

Dynavax Technologies Upcoming and Recent Events

Dynavax Technologies Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 25, 2020
Next Earnings ReportMay 13, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 25, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Dynavax Technologies Corporate Filings

Dynavax Technologies SEC Reporting

Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Financial Statements and Exhibits. Results of Operations and Financial Condition
Unclassified Corporate Event

Dynavax Technologies Corporate Directors

Stanley Plotkin Independent Director
Francis Cano Independent Director
Dan Kisner Independent Director
Additionally see Investing Opportunities. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Search macroaxis.com